{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:34:37Z","timestamp":1791902077920,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hematologic malignancies, including leukemias and lymphomas, remain life-threatening diseases for which preventive strategies have not yet been established. Recent studies have suggested that sodium-glucose cotransporter 2 (SGLT2) inhibitors have cancer-suppressive properties. This study investigated whether SGLT2 inhibitors are associated with reduced risk of hematologic malignancies in patients with diabetes, using a large-scale medical database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data of patients with diabetes prescribed diabetes medications were extracted from the JMDC Payer database (January 2005 to November 2023). After exclusions, patients were categorized into SGLT2 inhibitor (n\u2009=\u2009158\u2009877) and non-SGLT2 inhibitor (n\u2009=\u2009118\u2009678) groups. Propensity score matching, accounting for patient characteristics, resulted in 102\u2009478 matched patients per group. The primary endpoint was time to hematologic malignancy; secondary endpoints were time to lymphoma, leukemia, and their subcategories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of hematologic malignancies was lower in the SGLT2 inhibitor group than in the non-SGLT2 inhibitor group (P\u2009&amp;lt;\u2009.001, hazard ratio [HR]\u2009=\u20090.73, 95% CI = 0.62 to 0.86, risk difference at 5\u2009years (RD)\u2009=\u2009\u22120.16%). Lymphoma incidence was also lower in the SGLT2 inhibitor group (P\u2009=\u2009.003, HR\u2009=\u20090.71, 95% CI = 0.57 to 0.89, RD\u2009=\u2009\u22120.12%), whereas no clear evidence of difference was observed for leukemia (P\u2009=\u2009.06, HR\u2009=\u20090.76, 95% CI = 0.57 to 1.01, RD\u2009=\u2009\u22120.02%). Lymphocytic leukemia was associated with lower incidence compared to the non-SGLT2 inhibitor group (P\u2009=\u2009.04, HR\u2009=\u20090.44, 95% CI = 0.19 to 0.99, RD\u2009=\u2009\u22120.02%), whereas no clear evidence of difference was observed for myeloid leukemia (P\u2009=\u2009.12, HR\u2009=\u20090.76, 95% CI = 0.54 to 1.08, RD\u2009=\u2009\u22120.01%). Regarding acute myeloid leukemia (AML), the incidence was low in the SGLT2 inhibitor group (P\u2009=\u2009.001, HR\u2009=\u20090.34, 95% CI = 0.19 to 0.62, RD\u2009=\u2009\u22120.05%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibitor use may be associated with lower risk of hematologic malignancies in adults with diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag038","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:53:32Z","timestamp":1770382412000},"page":"1195-1202","source":"Crossref","is-referenced-by-count":2,"title":["Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7708-2855","authenticated-orcid":false,"given":"Takehiro","family":"Kawashiri","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women\u2019s College of Liberal Arts , Kyotanabe, Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8234-8786","authenticated-orcid":false,"given":"Masaki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hyogo Medical University , Kobe, Hyogo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5563-6730","authenticated-orcid":false,"given":"Tadashi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hyogo Medical University , Kobe, Hyogo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-9919","authenticated-orcid":false,"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9526-5934","authenticated-orcid":false,"given":"Shunsuke","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women\u2019s College of Liberal Arts , Kyotanabe, Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0507-7309","authenticated-orcid":false,"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Education and Research Center for Pharmacy Practice, Faculty of Pharmaceutical Sciences, Doshisha Women\u2019s College of Liberal Arts , Kyotanabe, Kyoto,","place":["Japan"]},{"name":"Department of Pharmacy, Kyushu University Hospital , Fukuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"2026070708471527200_djag038-B1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jclinepi.2015.09.017","article-title":"Timely disclosure of progress in long-term cancer survival: the boomerang method substantially improved estimates in a comparative study","volume":"70","author":"Brenner","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026070708471527200_djag038-B2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3949\/ccjm.84a.15159","article-title":"Living with hematologic cancer: recommendations, solutions","volume":"84","author":"Faiman","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"2026070708471527200_djag038-B3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"2026070708471527200_djag038-B4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.2174\/0929867324666171006144725","article-title":"Biological therapy of hematologic malignancies: toward a chemotherapy-free era","volume":"26","author":"Klener","year":"2019","journal-title":"Curr Med Chem"},{"key":"2026070708471527200_djag038-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.iac.2009.11.005","article-title":"A history of bone marrow transplantation","volume":"30","author":"de la Morena","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"2026070708471527200_djag038-B6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026070708471527200_djag038-B7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1124\/jpet.114.217992","article-title":"Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in Zucker Diabetic Fatty rats","volume":"351","author":"Kuriyama","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2026070708471527200_djag038-B8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.diabres.2014.07.020","article-title":"Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study","volume":"106","author":"Kadokura","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2026070708471527200_djag038-B9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2026070708471527200_djag038-B10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070708471527200_djag038-B11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070708471527200_djag038-B12","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026070708471527200_djag038-B13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2026070708471527200_djag038-B14","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026070708471527200_djag038-B15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026070708471527200_djag038-B16","doi-asserted-by":"publisher","first-page":"101585","DOI":"10.1016\/j.diabet.2024.101585","article-title":"Association of SGLT2 inhibitors with incident cancer","volume":"50","author":"Suzuki","year":"2024","journal-title":"Diabetes Metab"},{"key":"2026070708471527200_djag038-B17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.5414\/CP204465","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population","volume":"61","author":"Tanaka","year":"2023","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2026070708471527200_djag038-B18","doi-asserted-by":"publisher","first-page":"112864","DOI":"10.1016\/j.biopha.2022.112864","article-title":"Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans","volume":"149","author":"Nakachi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2026070708471527200_djag038-B19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.je20090066","article-title":"Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage","volume":"20","author":"Kimura","year":"2010","journal-title":"J Epidemiol"},{"key":"2026070708471527200_djag038-B20","volume-title":"StatPearls","author":"Chennamadhavuni","year":"2023"},{"key":"2026070708471527200_djag038-B21","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070708471527200_djag038-B22","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol Metab"},{"key":"2026070708471527200_djag038-B23","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.2147\/TT.S101333","article-title":"Therapy-related myeloid neoplasms: clinical perspectives","volume":"11","author":"Fianchi","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2026070708471527200_djag038-B24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026070708471527200_djag038-B25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.18433\/jpps31862","article-title":"Analysis of secondary leukemia and myelodysplastic syndrome after chemotherapy for solid organ tumors using the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Kawashiri","year":"2021","journal-title":"J Pharm Pharm Sci"},{"key":"2026070708471527200_djag038-B26","doi-asserted-by":"publisher","first-page":"1205836","DOI":"10.3389\/fonc.2023.1205836","article-title":"Radiation for hematologic malignancies: from cell killing to immune cell priming","volume":"13","author":"Dabaja","year":"2023","journal-title":"Front Oncol"},{"key":"2026070708471527200_djag038-B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3857\/roj.2018.00290","article-title":"Radiation induced secondary malignancies: a review article","volume":"36","author":"Dracham","year":"2018","journal-title":"Radiat Oncol J"},{"key":"2026070708471527200_djag038-B28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026070708471527200_djag038-B29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1182\/blood.2019001362","article-title":"Analysis of 153\u2009115 patients with hematological malignancies refines the spectrum of familial risk","volume":"134","author":"Sud","year":"2019","journal-title":"Blood"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag038\/66903389\/djag038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1195\/66903389\/djag038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1195\/66903389\/djag038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:49:57Z","timestamp":1783428597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/7\/1195\/8484093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,14]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag038","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,14]]}}}